6 Result(s)

Article

Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea

Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare ...

Brian E. Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson… in Advances in Therapy (2024)

Article

Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis

Patients with attention-deficit/hyperactivity disorder (ADHD) often have psychiatric comorbidities that may confound diagnosis and affect treatment outcomes and costs. The current study described treatment pat...

Jeff Schein, Ann Childress, Patrick Gagnon-Sanschagrin… in Advances in Therapy (2023)

Article

Opioid-Induced Constipation: Cost Impact of Approved Medications in the Emergency Department

Opioid-induced constipation (OIC) prescription medications (OIC-Rx) like methylnaltrexone subcutaneous (SC) have shown efficacy in treating OIC in the emergency department (ED). This study aimed to describe an...

W. Frank Peacock, Neal Slatkin, Patrick Gagnon-Sanschagrin… in Advances in Therapy (2022)

Article

Response to: Alfred Sandrock, Wildon Farwell. Letter to the Editor, Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8

Omar Dabbous, Benit Maru, Jeroen P. Jansen, Maria Lorenzi… in Advances in Therapy (2019)

Article

Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1

Infants with spinal muscular atrophy (SMA) type 1 typically face a decline in motor function and a severely shortened life expectancy. Clinical trials for SMA type 1 therapies, onasemnogene abeparvovec (AVXS-1...

Omar Dabbous, Benit Maru, Jeroen P. Jansen, Maria Lorenzi… in Advances in Therapy (2019)

Article

Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib as Adjuvant Therapy—A Retrospective Chart Extract-Based Approach

To compare characteristics of patients, the risk of recurrence, and mortality among adult patients with primary resectable gastrointestinal stromal tumor (GIST) receiving short-term (6–12 months) versus long-t...

Anthony Paul Conley, Annie Guérin, Medha Sasane… in Journal of Gastrointestinal Cancer (2013)